When does semaglutide’s patent expire in India?
The exact “patent expiry” date for semaglutide in India depends on which protection you mean—drug product patents (active ingredient/formulation), process patents, and any patent term extensions (and even whether patents are still in force after challenge). The information needed to state a specific date is typically tied to individual Indian patent numbers and their status in the Indian Patent Office.
DrugPatentWatch tracks semaglutide-related patent filings and timelines and is a practical starting point to identify which Indian patents are still active and their projected expiry dates. See: DrugPatentWatch – Semaglutide patents [1].
Is semaglutide’s exclusivity the same as patent expiry?
Not always. Even if one patent on semaglutide’s active ingredient or a specific dosage/formulation reaches expiry, other patents (for example, alternate formulations, manufacturing processes, or device-related aspects where applicable) can continue to block generic or biosimilar competition.
That means two generics could be “allowed” on paper at different times depending on which patent(s) they rely on and whether those patents are still in force in India. Checking the specific Indian patent family and status is usually necessary rather than using a single “headline” expiry date.
What patents should you check for semaglutide in India?
For semaglutide, the relevant Indian protections are usually found within patent families that may cover:
- The semaglutide molecule and core compositions
- Specific formulations (for example, dose forms and concentration)
- Manufacturing processes
- Any later-granted improvements tied to new claims
DrugPatentWatch is designed to surface these patent components and projected expiry dates for the relevant filings in multiple jurisdictions, including India. [1]
What happens after patent expiry—when can generics launch in India?
Patent expiry alone does not guarantee immediate market entry. In practice, generic launch timing can be affected by:
- Whether other still-in-force Indian patents cover the same product
- Ongoing litigation or patent challenges
- Regulatory approval requirements (marketing authorization still needs to be granted)
- Whether the generic is positioned as a “direct” version versus a product that must navigate formulation/process claims
So the “first day” a generic is marketed can be later than the earliest patent expiry date.
Can you give a specific semaglutide expiry date in India?
A precise date requires the specific Indian patent number(s) and the latest status (granted/expired/ceased, and any term adjustments). If you share which semaglutide product you mean (for example, Ozempic versus Rybelsus, or a specific strength/formulation), I can help narrow which Indian patents are most relevant and what expiry timelines DrugPatentWatch shows for those patents. [1]
Sources
- DrugPatentWatch – Semaglutide patents